A Phase 3, Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Conjugate Vaccine, in Pneumococcal Vaccine-Naïve Adults 18–64 Years of Age at Increased Risk of Pneumococcal Disease, STRIDE-8

Journal:

Clinical Infectious Diseases

Published:

2025-11-10

DOI:

10.1093/cid/ciaf604

Affiliations:

10

Authors:

16

Go to article

Institutions	Authors	Share
Merck & Co, United States of America (USA)	8.000000	0.50
JCHO Shimonoseki Medical Center, Japan	1.000000	0.06
McMaster University, Canada	1.000000	0.06
Universidad San Sebastián (USS), Chile	1.000000	0.06
CGM Research Trust, New Zealand	1.000000	0.06
Medical Corporation Applied Bio-Pharmatech Kurume Clinical Pharmacology Clinic, Japan	1.000000	0.06
Konkuk University Medical Center (KUMC), South Korea	1.000000	0.06
Medical University of Lublin, Poland	1.000000	0.06
The Prince Charles Hospital (TPCH), Australia	0.500000	0.03
Royal Brisbane and Women's Hospital (RBWH), Australia	0.500000	0.03

Interested in Immunology?